Effect of topical compound of erythromycin with zinc acetate versus topical erythromycin on treatment of mild to moderate acne vulgaris

Effect of topical compound of erythromycin with zinc acetate versus topical erythromycin on treatment of mild to moderate acne vulgaris: a double-blind randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N397

Enrollment

Registered

2021-05-26

Start date

2021-05-22

Completion date

Unknown

Last updated

2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne vulgaris. Acne vulgaris

Interventions

Intervention 1: Intervention group: Topical compound of erythromycin 4% and zinc acetate 1.2% twice daily for 3 months. Intervention 2: Control group: Topical compound of erythromycin 4% twice daily f

Eligibility

Sex/Gender

All

Age

12 Years to 75 Years

Inclusion criteria

Inclusion criteria: Age of 12 to 75 years, Mild to moderate acne vulgaris

Exclusion criteria

Exclusion criteria: Pregnancy or breastfeeding, Sensitivity to erythromycin or zinc acetate, History of taking oral isotretinoin during the last 6 months, History of taking oral estrogen compounds during the last 3 months, History of using retinoid and antibiotic compounds during the last 1 month, History of using antimicrobial soap and topical exfoliators during the last 2 weeks, Chronic skin diseases such as psoriasis, lichen planus, and vitiligo, Immunodeficiency disorder or using immunosuppressive drugs

Design outcomes

Primary

Measure	Time frame
Severity of acne lesions. Timepoint: Before the intervention and 1 and 2 and 3 months after the intervention. Method of measurement: Using the Global Acne Grading System (GAGS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Zahra Moradhaseli

Hamedan University of Medical Sciences

dr.zahra.m1368@gmail.com+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026